Terms ending in 2038
Every in-force patent on Biodesix, Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,150,238 | Method for Identification of Cancer Patients with Durable Benefit from Immunotherapy in Overall Poor Prognosis Subgroups In force · High confidence | Biodesix, Inc. | In force | High confidence | |
| US 11,594,403 | Predictive Test for Prognosis of Myelodysplastic Syndrome Patients Using Mass Spectrometry of Blood-Based Sample In force · High confidence | Biodesix Inc. | In force | High confidence | |
| US 10,870,891 | Diagnostic Test Stystem for Specific, Sensitive and Reproducible Detection of Circulating Nucleic Acids in Whole Blood In force · High confidence | Biodesix, Inc. | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.